Agents and Actions

, Volume 15, Issue 5–6, pp 494–499 | Cite as

Histidine decarboxylase inhibition: A novel approach towards the development of an effective and safe gastric anti-ulcer drug

  • N. S. Parmar
  • G. Hennings
  • O. P. Gulati
Histamine and Kinins


The involvement of histamine in mediating gastric function under normal and pathological conditions has been largely established. The relationship between gastric acid production and peptic ulcer diathesis is also well known. Recently, endogenous histamine formation and its release from mast cells has been implicated in the pathogenesis of human and experimental gastric ulcers produced by restraint and pyloric ligation. It has also been implicated in the gastric mucosal damage produced by drugs like aspirin, phenylbutazone and reserpine. These observations suggest that histidine decarboxylase inhibitors may be useful in the prevention of such lesions. Our studies on the evaluation of some histidine decarboxylase inhibitors show that these compounds have a promising potential for developing an effective and safe anti-ulcer drug. This mini-review incorporates the results of our studies which have been adequately supported by other studies as well.


Aspirin Mast Cell Histamine Peptic Ulcer Gastric Ulcer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    G. Kahlson, E. Rosengren, D. Svahn andR. Thunberg,Mobilization and formation of histamine in the gastric mucosa as related to gastric secretion, J. Physiol., Lond.174, 400–416 (1964).Google Scholar
  2. [2]
    P.A. Shore,Release of histamine from the stomach by vagus stimulating drugs: association with gastric acid secretion, Fedn Proc.24, 1322–1326 (1965).Google Scholar
  3. [3]
    R.J. Levine,Effect of histidine decarboxylase inhibition on gastric acid secretion in the rat, Fedn Proc.24, 1331–1333 (1965).Google Scholar
  4. [4]
    B.J. Haverback, M.I. Stubrin andB.J. Dyce,Relation of histamine to gastrin and other secretogogues. Fedn Proc.24, 1326–1330 (1965).Google Scholar
  5. [5]
    P.K. Rangachari,Histamine release by gastric stimulants. Nature, Lond.253, 53–55 (1975).Google Scholar
  6. [6]
    B.O. Amure andM. Ginsburg,Inhibitors of the histamine catabolism and the action of gastrin in the rat, Br. J. Pharmac.23, 476–485 (1976).Google Scholar
  7. [7]
    R.W. Schayer,Catabolism of physiological quantities of histamine in vivo, Physiol. Rev.39, 116–120 (1959).PubMedGoogle Scholar
  8. [8]
    J.W. Black, W.A.M. Duncan, C.J. Durant, C.R. Ganellin andE.M. Parsons,Definition and antagonism of histamine H 2 receptors, Nature, Lond.236, 385–390 (1972).Google Scholar
  9. [9]
    J.I. Isenberg,A new look at peptic ulcer, Ann. intern. Med.84, 57–67 (1976).PubMedGoogle Scholar
  10. [10]
    C.F. Code,Reflections on histamine gastric secretion and the H 2 receptor New Engl. J. Med.296, 1459–1462 (1977).PubMedGoogle Scholar
  11. [11]
    D. Brodie, R. Marshal andO. Moreno,Effect of restraint on gastric acidity in the rat, Am. J. Physiol.202, 812–814 (1962).PubMedGoogle Scholar
  12. [12]
    R.J. Levine andE.C. Senay,Studies on the role of acid in the pathogenesis of experimental stress ulcers, Psychosom. Med.32, 61–65 (1970).PubMedGoogle Scholar
  13. [13]
    S. Dai andC.W. Ogle,Histamine H 2 receptor blockade: effect on methacholine induced gastric secretion in rats, IRCS med. Sc.3, 236–237 (1975).Google Scholar
  14. [14]
    P.H. Guth andP. Hall,Microcirculatory and mast cell'change in restraint induced gastric ulcers, Gastroenterology50, 562–570 (1966).PubMedGoogle Scholar
  15. [15]
    R.J. Levine andE.C. Senay,Histamine in the pathogenesis of stress ulcer in the rat, Am. J. Physiol.214, 892–896 (1968).PubMedGoogle Scholar
  16. [16]
    W. Lorenz andG. Feifel,Neue Gesichtspunkte zur Pathogenese des Streß- und Steroidulkus, Dt. med. Wschr.95, 1848–1850 (1970).Google Scholar
  17. [17]
    J.C. Schwartz, Y. Cohen andG. Valette,Histidine decarboxylase gastrique et ulceres experimentaux chez le rat, Biochem. Pharmac.15, 2122–2124 (1966).CrossRefGoogle Scholar
  18. [18]
    A.A.N. Abdel-Galil andP.B. Marshal,Phenylbutazone and histamine formation in rat glandular stomach: its relationship to gastric ulceration, Br. J. Pharmac.33, 1 (1968).Google Scholar
  19. [19]
    A. Kohut andA. Nicak,Effect of epinephrine, epinephrectomy and adrenodemedulation in phenylbutazone gastric ulceration in the young and adult rat. 4th International Congress of Pharmacology, Abstracts, 106 (1969).Google Scholar
  20. [20]
    K.P. Bhargava, M.B. Gupta andK.K. Tangri,Mechanism of ulcerogenic activity of indomethacin and oxyphenbutazone, Eur. J. Pharmac.22, 191 (1973).CrossRefGoogle Scholar
  21. [21]
    M. Daas, M.B. Gupta andK.P. Bhargava,Biogenic amines in the pathogenesis of gastric ulceration induced by aspirin in rats, Indian J. med. Res.65, 273–278 (1977).PubMedGoogle Scholar
  22. [22]
    C.W. Ogle andH.K. Lau,Disodium cromoglycate: a novel gastric anti-ulcer agent, Eur. J. Pharmac.65, 411–414 (1979).CrossRefGoogle Scholar
  23. [23]
    H.K. Lau andC.W. Ogle,A comparative study of the gastric ulcerogenic effects of stress and reserpine in rats with decreased stomach wall mast cell populations, Experientia36, 995–996 (1980).PubMedGoogle Scholar
  24. [24]
    S. Dai, C.W. Ogle andC.H. Lo,The effects of metiamide on gastric secretion and stress ulceration in rats, Eur. J. Pharmac.33, 277–282 (1975).CrossRefGoogle Scholar
  25. [25]
    S. Okabe, K. Takeuchi, T. Murata andK. Takagi,Effects of cimetidine and atropine sulphate on gastric secretion and healing of gastric and duodenal ulcers in rats. Eur. J. Pharmac.41, 205–208 (1977).CrossRefGoogle Scholar
  26. [26]
    H.H. Lauterbach andP. Mattes,Effect of cimetidine, histamine H 2 receptor antagonist in the prevention of experimental stress ulcer in the rat, Eur. Surg. Res.10, 105–108 (1978).PubMedGoogle Scholar
  27. [27]
    A.S. Macdonald, B.J. Steele andM.G. Bottomley,Treatment of stress induced upper gastro-intestinal haemorrhage with metiamide, Lancet1, 68–69 (1976).CrossRefPubMedGoogle Scholar
  28. [28]
    R.E. Pounder, R.H. Hunt, M.A. Stekelman, G.J. Milton-Thompson andJ.J. Misiewicz,Healing of gastric ulcer during treatment with cimetidine, Lancet1, 327–328 (1976).Google Scholar
  29. [29]
    D.H. Winship,Cimetidine in the management of duodenal ulcers, Gastroenterology74, 402–406 (1978).PubMedGoogle Scholar
  30. [30]
    J.P. Gee, L.K. Jim, A. Leibowitz andD.C. McLeod,A prospective review of cimetidine use, Drug Intell. Clin. Pharm.13, 567–571 (1979).Google Scholar
  31. [31]
    R.R. Schade andR.M. Donaldson,How physicians use cimetidine. A survey of hospitalized patients and published cases, New Engl. J. Med.304, 1281–1284 (1981).Google Scholar
  32. [32]
    S. Deflora,Cimetidine, ranitidine and their mutagenic nitroso derivatives, Lancet2, 993–994 (1981).CrossRefGoogle Scholar
  33. [33]
    R. Brimblecome,Cimetidine, nitrosation and carcinogenicity, Lancet2, 686–687 (1981).CrossRefGoogle Scholar
  34. [34]
    S. Deflora andA. Picciotto,Mutagenicity of cimetidine in nitrite enriched human gastric juice, Carcinogen.1, 925–930 (1981).Google Scholar
  35. [35]
    P.N. Magee, N.J. Mac Mortensen andW.K. Eltringham,Cimetidine, nitrosation and cancer, Lancet 984–992.Google Scholar
  36. [36]
    W.P. Ritchie, Jr. J.J. Breen andD.I. Griggs,Prevention of stress ulcer by reducing gastric tissue histamine, Surgery62, 596–600 (1967).PubMedGoogle Scholar
  37. [37]
    K.-F.R. Sewing andB. Binder, The effect of brocresine (NSD 1055) on diamine oxidase levels in the rat plasma, liver, stomach, and upper small intestinein vivo andin vitro. InHistamine p. 306 (Ed.Cz. Maslinski). Dowden, Hutchinson and Ross, Stroudsberg, Pennsylvania. 1973.Google Scholar
  38. [38]
    W. Lorenz, J. Kusche, H. Barth andCh. Mathias, Action of several flavonoids on enzyme of histidine metabolismin vitro. InHistamine, pp. 265–269 (Ed.Cz. Maslinski). Dowden, Hutchinson and Ross, Stroudsberg, Pennsylvania 1973.Google Scholar
  39. [39]
    W. Lorenz, H.-J. Reimann, J. Kusche, H. Barth, A. Schmal, A. Nusime, G. Schulte, R. Frolich, J. Schmidt andR. Raabe,Effects of (+)-catechin on several enzymes of histamine metabolism and on stress ulcer formation in the female rat, Naunyn-Schmiedeberg's Arch. Pharma. Suppl.287, 62 (1975).Google Scholar
  40. [40]
    T.F. Slater andM.N. Eakins, Interactions of (+)-cyanidanol-3 with free radical generating systems. InNew Trends in the Therapy of Liver Diseases, pp. 84 (Ed.H.A. Bertelli). Karger, Basel, 1975.Google Scholar
  41. [41]
    G. Hennings, Biochemical, pharmacological and toxicological evaluation of (+)-cyanidanol-3. InInternational Workshop on (+)-Cyanidanol-3 in Diseases of the Liver, pp. 6–9 (Ed.H.-O. Conn). The Royal Society of Medicine, Academic Press, London 1981.Google Scholar
  42. [42]
    P. Wendt, H.-J. Reimann, K. Swoboda, G. Hennings andG. Blumel,The use of flavonoids as inhibitors of histidine decarboxylase in gastric diseases, Experimental and clinical studies, Naunyn-Schmiedeberg's Arch. Pharma. Suppl.313, 238 (1980).Google Scholar
  43. [43]
    H.-J. Reimann, W. Lorenz, M. Fischer, R. Frolich, H.-J. Meyer andA. Schmal,Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro, Agents and Actions7, 69–72 (1977).Google Scholar
  44. [44]
    N.S. Parmar,A pharmacological study on the effects of some bioflavonoids on experimentally induced inflammation, increased vascular permeability, gastric ulcers and galactosemic cataracts, Ph.D. Thesis, University of Madras, India (1977).Google Scholar
  45. [45]
    N.S. Parmar andM.N. Ghosh,Gastric anti-ulcer activity of (+)-cyanidanol-3, a histidine decarboxylase inhibitor. Eur. J. Pharmac.69, 25–32 (1981).CrossRefGoogle Scholar
  46. [46]
    N. Albertani-Borowski,3-Methoxy-5,7,3′4′-tetrahydroxyflavan, Drugs of the Future8, 209 (1983).Google Scholar
  47. [47]
    N.S. Parmar andM.N. Ghosh, Gastric anti-ulcer activity of 3-O-methyl-(+)catechin. InStudies in Organic Chemistry, Vol. 11, pp. 513–521 (EdsF. Farkas, M. Gabor, F. Kallay andH. Wagner). Elsevier, Amsterdam 1982.Google Scholar
  48. [48]
    N.S. Parmar andG. Hennings.The effect of 3-methoxy-5,7,3′4′-tetrahydroxyflavan on the restraint induced gastric ulceration augmented by aspirin, a gastric mucosal barrier breaker, Res. Comm. Chem. Path. & Pharmac.41, 337–340 (1983).Google Scholar
  49. [49]
    N.S. Parmar andG. Hennings,The gastric antisecretory activity of 3-methoxy-5,7,3′4′-tetrahydroxyflavan (ME) — a specific histidine decarboxylase inhibitor in rats, Agents and Actions, 1984, In press.Google Scholar
  50. [50]
    A.M. Hackett andL.A. Griffiths,The metabolism and excretion of 3-O-methyl-(+)-catechin in the rat, mouse and marmoset, Drug Metabolism & Excretion9, 54 (1981).Google Scholar
  51. [51]
    L.A. Griffiths,Topics in Flavonoid Chemistry and Biochemistry, p. 201 (EdsL. Farkas,M. Gabor andF. Kally) Elsevier, Amsterdam 1975.Google Scholar
  52. [52]
    N. Albinus, G. Frisch andG. Hennings,Histidine decarboxylase inhibition by O-methyl-3-(+)-catechin and gastric acid secretion in the cat, Agents and Actions13, 249–251 (1983).PubMedGoogle Scholar
  53. [53]
    N.S. Parmar andG. Hennings,The gastric antiulcer activity of 3-methoxy-5,7,3′,4′-tetrahydroxyflavan a specific histidine decarboxylase (HDC) inhibitor. 43rd International Congress of Pharmaceutical Sciences, Montreux, 5–9 Sept. 1983. FIP Abstracts 171 (1983).Google Scholar
  54. [54]
    D.P. Ganote, G. Hennings andP.W. Lucker, (+)-3-Methoxy-5,7,3′,4′-tetrahydroxyflavan (ME): a new compound to prevent gastric irritation. A gastric potential difference analysis, Meth. and Find. Exptl. Clin Pharmacol.5, 489–494 (1983).Google Scholar
  55. [55]
    H. Laule, P.W. Lucker, P. Altmayer andM.A. Eldon,Gastric potential difference as a model in clinical pharmacology: assessment of gastric mucosal response to aspirin, Eur. J. Clin. Pharmacol.22, 147–151 (1982).CrossRefPubMedGoogle Scholar
  56. [56]
    J. Kollonitsch, A.A. Patchett, S. Marburg, A.L. Maycock, L.M. Perkins, G.A. Doldouras, D.E. Duggan andS.D. Aster,Selective inhibitors of biosynthesis of aminergic neurotransmitters, Nature274, 906–908 (1978).PubMedGoogle Scholar
  57. [57]
    M. Garbarg, G. Barbin, E. Rodergas andJ.C. Schwartz,Inhibition of histamine synthesis in brain by fluoromethylhistidine, a new irreversible inhibitor, in vitro and in vivo studies, J. Neurochem.35, 1045–1048 (1980).PubMedGoogle Scholar
  58. [58]
    B. Lippert, P. Bey, V. Dorsselaer, J.P. Vevert, C. Danzin, G. Ribereau-Gayon andM.J. Jung,Selective irreversible inhibition of mammalian histidine decarboxylase by chloromethylhistidine, Agents and Actions9, 38–39 (1979).PubMedGoogle Scholar
  59. [59]
    M. Bouclier, M.J. Jung andF. Gerhart,Inhibition of histamine biosynthesis and gastric function in the rat: effect on pentagastrin induced gastric secretion, Agents and Actions13, 241–246 (1983).PubMedGoogle Scholar
  60. [60]
    M. Mattsson, A. Henningsson, S. Henningsson, andL. Hammar,Effect of His-Phe, a competitive inhibitor of histidine decarboxylase, on gastric acid secretion in chronic gastric fistula rats. Delay in acid acid secretion response to pentagastrin, Agents and Actions12, 176–178 (1982).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1984

Authors and Affiliations

  • N. S. Parmar
    • 1
  • G. Hennings
    • 2
  • O. P. Gulati
    • 3
  1. 1.Faculty of PharmacyKing Saud UniversityRiyadhSaudi Arabia
  2. 2.Zyma GmbHMunchen-70West Germany
  3. 3.Zyma SANyonSwitzerland

Personalised recommendations